Featured Research

from universities, journals, and other organizations

Considering Usual Medical Care In Clinical Trial Design

Date:
September 28, 2009
Source:
Public Library of Science
Summary:
In a new paper, researchers discuss the scientific and ethical issues associated with choosing clinical trial designs when there is no consensus on what constitutes usual care.

In this week's PLoS Medicine, Liza Dawson (National Institutes of Health) and colleagues discuss the scientific and ethical issues associated with choosing clinical trial designs when there is no consensus on what constitutes usual care.

For example, in 2002 a clinical trial designed to evaluate the best way of ventilating patients with a severe lung condition called acute respiratory distress syndrome sparked a major controversy.

Critics charged that management of the condition in the different arms of the study did not adequately reflect usual medical care, and alleged that it was essential for scientific and ethical reasons to have a usual care comparison arm in the study.

The controversy over trial design enmeshed the National Institutes of Health (NIH), the Office for Human Research Protections (OHRP) and the critical care research community. The trial was put on hold and reviewed by two independent expert panels. Experts pointed to the need for further analysis of the scientific and ethical issues involved in choosing trial designs when there is no consensus on standard of care.

Dawson and colleagues discuss these issues in their policy paper. They enumerate five factors that make consensus on these issues particularly difficult, and recommend specific criteria for assessing proposed study designs.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Dawson L, Zarin DA, Emanuel EJ, Friedman LM, Chaudhari B, et al. Considering Usual Medical Care in Clinical Trial Design. PLoS Med, 2009; 6(9): e1000111 DOI: 10.1371/journal.pmed.1000111

Cite This Page:

Public Library of Science. "Considering Usual Medical Care In Clinical Trial Design." ScienceDaily. ScienceDaily, 28 September 2009. <www.sciencedaily.com/releases/2009/09/090928201843.htm>.
Public Library of Science. (2009, September 28). Considering Usual Medical Care In Clinical Trial Design. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/09/090928201843.htm
Public Library of Science. "Considering Usual Medical Care In Clinical Trial Design." ScienceDaily. www.sciencedaily.com/releases/2009/09/090928201843.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins